Abstract
In 1941 Huggins and Hodges published for the first time the favorable effects of surgical castration and estrogen treatment on the progression of metastatic prostate cancer. However, this hormonal therapy is not without side effects. Since this pioneering milestone in history of prostate cancer, a further tremendous innovation did not take place. Today, due to intensive clinical, biochemical, nuclear-biological and molecular-biological research, many hormone active treatment variations are available. Besides traditional hormonal therapy, surgical or chemical castration, maximal androgen blockade, nontraditional forms of hormonal therapy, intermittent hormonal therapy, antiandrogens, 5-α-reductase inhibitors, and their combinations, we discuss options toward creating an increased number of side effect-oriented offers of hormonal treatment options, guaranteeing a longer and more comfortable exhaustion of the individual hormonal period of response and probably a longer survival. The prerequisite is a closer-than-ever monitoring by tumor marker and an early observation of symptomatic changes.
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The introduction of hormonal therapy (HT) in the treatment of prostate cancer (PC) by Huggins and Hodges (1941) in the 1940s was like a thunderbolt. However, despite intensive basic research on the field of hormonal receptors and of testosterone (T) bioconversion and a better understanding of the endocrine mechanisms of action and inhibition in endocrine-active organs, a further pioneering development has not been achieved. The first-line standard option in virginal metastatic PC remains the androgen blockade achieved today with minimal side effects using luteinizing hormone-releasing hormone (LHRH) analogs. Low-priced, equally effective alternatives to hormone deprivation such as orchiectomy with the disadvantage of morbidity and irreversibility had to give way to the demand for a better quality of life (Fowler et al. 2002; Potosky et al. 2002) . Due to their high rate of cardiovascular and hepatogenic complications, estrogens had fallen out of favor until recently. Today a renaissance may be expected as the transdermal form of parenteral applications, avoiding hepatic first-pass metabolism, seems to be as effective as LHRH analogs, prevents andropause symptoms, improves quality of life scores, and increases bone density. It could be shown recently that this estrogenic compound induces a prostate-specific antigen (PSA)-response in patients with hormone-refractory PC (HRPC). It is important to mention that the transdermal application of estradiol costs a tenth of current therapy (Ockrim et al. 2004 (Ockrim et al. , 2005 .
In the last few years, survival and quality of life have improved due to modern hormonal treatment options consisting of many endocrine-active drugs, closer monitoring of tumor markers, early observation of symptomatic changes, and use of different hormone-active substances in a secondary and even tertiary setting before nonhormonal treatment is indicated. In the case of metastatic PC, the average duration of response to castration was between 18 and 24 months 20 years ago. Further survival was rarely longer than 6 months. Nowadays these patients survive twice as long on average (Sharifi et al. 2005) . Therefore, delaying the onset of a true hormonerefractory state and exhausting all possible forms of hormonal manipulations before starting effective chemotherapy is a reasonable strategy. Today PSA values are followed more closely in actively treated patients. Early change from a treatment that effectively has been exhausted to one that may be by now of benefit is possible. In this paper we give a summarized report of today's treatment options for patients with locally confined PC, for patients in PSA progress after curative treatment, for those with locally advanced PC, for those with distant metastases, and for those progressing in hormonal relapse.
Locally Confined Prostate Cancer (T1-2 N0 M0)
In T1/T2 PC, curative treatment is indicated. Especially in young patients, radical prostatectomy (RP) is the first treatment option. In pT1 and pT2 tumors, no further therapy is needed. There is no place for adjuvant androgen deprivation therapy (AD) or maximal androgen blockade (MAB) because, due to the side effects, survival may even worsen. Recently, the members of the Early Prostate Cancer (EPC) program (Wirth et al. 2004; Iversen et al. 2004; Iversen 2005) reported experiences with patients with localized and locally advanced PC. The EPC program comprised three randomized, double-blind, placebo-controlled trials. Altogether 8,113 patients had RP (55%), radiotherapy (RT) (17%) or watchful waiting (25%) as standard care, and thereafter they were randomized into a bicalutamide 150 mg/day arm (n=4,052) or a standard care only arm (placebo; n=4,061). Bicalutamide led to a significantly improved progression-free survival in the overall population. Overall survival was similar in the bicalutamide and placebo groups, across the program, and in each trial. However, in the patients primarily treated with watchful waiting, overall survival appeared to be reduced in patients with localized tumors treated with bicalutamide. The authors concluded that there is no indication for RP and adjuvant HT in patients with localized disease and with low risk. RT is also a curative treatment option. In low-risk T1a-T2b N0 M0 PC patients (Gleason score<7, PSA<10 ng/ml), the recommendation is for external RT up to 70-72 Gy. In intermediate-risk T2b PC patients (Gleason score 7, PSA 10-20 ng/ml), dose-escalating RT up to 76-81 Gy becomes necessary. Additive adjuvant HT does not improve the outcome (Wirth et al. 2004; Iversen et al. 2004; Tyrrell et al. 2005) . However, the high-risk tumor T2c and upward (Gleason score>7, PSA>20 ng/ml) often has not been treated sufficiently by dose escalating RT alone. Adjuvant HT is of significant benefit when there is a possibility of a not-yet-detectable lymph node involvement, or tumor spread outside the pelvis (Aus et al. 2005 ). D' Amico et al. (2004) reported a survival benefit in a randomized controlled study for the management of high-risk patients with clinically localized PC treated with 70 Gy three-dimensional conformal RT in combination with 6 months of HT. Eligible patients included those with PSA at least 10 ng/ml, a Gleason score of at least 7, or radiographic evidence of extraprostatic disease. After a median follow-up of 4.52 years, patients randomized to receive RT plus HT had a significantly higher survival (p<0.04), a lower PC-specific mortality (p<0.02), and a higher survival free of salvage HT (p<0,002). Granfors et al. (1998) confirmed the above findings. In a prospective randomized study they compared orchiectomy and external RT versus RT alone for nonmetastatic PC with or without pelvic lymph node involvement. There were 91 patients enrolled. Patients with early stage and well or moderately well differentiated T1-2 N0 tumors were excluded from the study. After a median follow-up of 9.3 years, clinical
